This is tagline here

Begbroke Science Park > News and Press > Oxford Nutrascience enters Brazilian pharmaceutical market with commercial agreement
Please set your featured image

Oxford Nutrascience enters Brazilian pharmaceutical market with commercial agreement

oxford nutrscience logo

Oxford Nutrascience the speciality pharmaceutical company using pharmaceutic and drug delivery scienceto develop advanced medicines, has signed an exclusive licensing and distribution agreement with AchéLaboratórios Farmacêuticos S.A., (“Aché”), one of Brazil’s largest pharmaceutical companies.

Under the terms of the seven year agreement Oxford Nutrascience will supply Aché with healthcare productswhich will be sold under Ach&eactue;’s women’s health brand, called ‘Inellare’.

It is anticipated that Oxford Nutrascience, using its own intellectual property, will develop a number ofpharmaceutical products for Aché, as the Brazilian pharmaceutical company expands its ‘Inellare’ productrange.

Using its extensive physician sales network around Brazil, Aché will distribute Oxford Nutrascience’sproducts into the fast growing consumer healthcare market.

This agreement represents a significant progression for Oxford Nutrascience and it is intended that therelationship with Aché will provide Oxford Nutrascience with access to the higher value pharmaceuticalindustry in Brazil. The Company’s strategy is to increase its focus on developing product innovation forpharmaceutical companies leveraging advanced pharmaceutic and drug delivery technology.

Brazil has one of the largest and most dynamic pharmaceutical markets in the emerging economies,reaching US$22.9 billion in 2010, with 2.06 billion pharmaceutical units (pills, tablets, medicine doses,among other units used). Source: IMS Health.

Brazil’s OTC market is forecast to grow by approximately 5.7% per annum from 2007 to 2012, making thetotal size of the market expected to be US$6.5bn by 2012*

Nigel Theobald, Chief Executive, Oxford Nutrascience Group Plc

“Working with Aché demonstrates our capability to partner with major pharmaceutical companies who areseeking product innovation. The big pharma companies are attracted by our ability to apply novelpharmaceutic technology to extend the lifecycle of existing branded generic medicines, which they haveoften invested many millions of dollars into.”

“Aché has significant commercial infrastructure in Brazil and the growth of Brazilian pharmaceutical productsis making the country one of the most important global markets for pharmaceutical companies. Our objectiveis to target this sector by working closely with Aché.

“Oxford Nutrascience continues to punch above its weight and it is encouraging that our other productdevelopment and IP, looking initially into the areas of nonsteroidal anti-inflammatory drugs continues toattract significant interest from potential commercial partners.

“We look forward to working with Aché in one of the fastest growing pharmaceutical markets in Brazil.”

Julio Conejero, Managing Director of the OTC & Generics Business Unit at Aché LaboratóriosFarmacêuticos S.A., said:”Aché has a successful track record of working with innovative companies and successfully launching theirproducts into the Brazillian market using our highly trained sales representatives. We are excited about theprospects of our agreement with Oxford Nutrascience and their product pipeline.”

“We are very pleased to have entered this partnership with Oxford Nutrascience which gives us access tocutting edge technology and expertise to develop innovative high quality products.”

For further information click here

Ben Roeves